Latest News - Dry Eye

Monday, February 05, 2018 | Clinical Trials, Dry Eye, Johnson & Johnson Vision Care

Johnson & Johnson Vision Announces Publication of Two Studies in Clinical Ophthalmology Demonstrating Effectiveness of LipiFlow as Treatment of MGD

Johnson & Johnson Vision announced the simultaneous publication of two studies in Clinical Ophthalmology demonstrating the patient and clinical benefits of LipiFlow treatment for meibomian gland d…

Read the full story

Wednesday, January 17, 2018 | Dry Eye, Allergan, Imprimis Pharmaceuticals

FDA Issues Warning Letter to Imprimis for False and Misleading Claims

The FDA has issued a warning letter to Imprimis Pharmaceuticals, claiming the maker of compounded drugs made false or misleading claims about its products. The FDA stated that Imprimis made misleading…

Read the full story

Wednesday, January 10, 2018 | Dry Eye, Allergan

Don't Expect Restasis Generics Until At Least Next Quarter, Allergan CEO Says

Update on those Restasis generics Allergan investors have been seriously dreading: The company now believes they’re “unlikely” to arrive before the second quarter, CEO Brent Saunders…

Read the full story

Tuesday, January 09, 2018 | Dry Eye, Medical Studies

Global Dry Eye Treatment Revenues to Grow to $4.9 Billion by 2022

Market Scope expects the global dry eye treatments market to grow at a healthy pace through 2022, as 2017 revenues of $3.7 billion climb to $4.9 billion. Revenues will climb most sharply in emerging m…

Read the full story

Friday, January 05, 2018 | Clinical Trials, Dry Eye, Kala Pharmaceuticals

Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials of KPI-121 0.25% in Dry Eye Disease

Kala Pharmaceuticals announced topline results from its two phase 3 clinical trials, STRIDE 1 and STRIDE 2 (STRIDE - Short Term Relief In Dry Eye), evaluating the safety and efficacy of KPI-121 0.25% …

Read the full story

Thursday, January 04, 2018 | Dry Eye, Optometry, TearLab Corp.

TearLab Submits 510(k) for FDA Clearance of TearLab Discovery Platform

TearLab announced that it has submitted a 510(k) application to the FDA for the potential clearance of its TearLab Discovery Platform, the company's next-generation in-vitro diagnostic testing sys…

Read the full story

Wednesday, January 03, 2018 | Dry Eye, Shire

Xiidra Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease

Shire announced that Xiidra (lifitegrast ophthalmic solution 5%), a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adults, has been approved …

Read the full story

Wednesday, December 27, 2017 | Dry Eye, Sun Pharma

FDA Accepts Sun Pharma's NDA for OTX-101 to Treat Dry Eye Disease

Sun Pharmaceutical Industries announced that the FDA has accepted a new drug application (NDA) filed by its US-based wholly owned subsidiary for OTX-101 (cyclosporine A, ophthalmic solution) 0.09%, a …

Read the full story

Thursday, December 07, 2017 | Dry Eye, Product Releases, Novaliq

Novaliq’s NovaTears+Omega-3 Approved in Europe for the Treatment of Evaporative Dry Eye Disease

Novaliq announced the European registration of NovaTears+Omega-3 for the enhanced treatment of the signs and symptoms of evaporative dry eye disease (DED). Using Novaliq’s proprietary, water-…

Read the full story

Thursday, November 09, 2017 | Dry Eye, Milestones, Johnson & Johnson Vision Care, TearScience

Johnson & Johnson Vision Announces TearScience LipiScan and LipiFlow Now Available in More Than 800 Eye Care Practices

TearScience, now a part of Johnson & Johnson Vision, announced at the American Academy of Ophthalmology (AAO) 2017 Meeting that its LipiScan and LipiFlow technologies are now available in more tha…

Read the full story

Wednesday, October 25, 2017 | Dry Eye, Medical Studies

Study: Patients Using Rohto Dry Aid Report All-Day Relief of Ocular Signs and Symptoms of Dry Eye Disease

Rohto Dry Aid, a new over-the-counter (OTC) lubricant eye drop was found to show superior relief of discomfort associated with visual tasking activities, and may provide a longer duration of symptomat…

Read the full story

Friday, October 20, 2017 | Dry Eye

Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye Syndrome

Aurinia Pharmaceuticals announced plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD). Additionally, Aurinia announced…

Read the full story

Thursday, October 19, 2017 | Dry Eye, Product Releases, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals to Offer Compounded Cyclosporine

Imprimis Pharmaceuticals announced it is making compounded cyclosporine-based formulations for dry eye disease. The formulations, which will be packaged in a preservative-free bottle, are patent-pendi…

Read the full story

Monday, October 02, 2017 | Awards, Dry Eye, Novaliq

German Ophthalmological Society (DOG) Honors Uta Gehlsen, PhD, for Research On the Use of Semifluorinated Alkanes in Dry Eye Treatment

The German Ophthalmological Society (DOG) presented Uta Gehlsen, PhD, Ocular Surface Group, Department of Ophthalmology, University of Cologne, with the “Dry Eye and Blepharitis/MGD” Award…

Read the full story

Monday, October 02, 2017 | Corporate Lawsuits, Dry Eye, Allergan, Shire

Shire Alleges Allergan Blocked Drug From Medicare Contracts

Shire filed an antitrust suit against Allergan alleging Allergan’s contracts with Medicare Part D drug plans for its Restasis eye drops effectively blocked access to Shire’s rival drug, ac…

Read the full story
Load More